Metformin inhibits the progression of castration-resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation
Cancer Letters · 2025-07 · 622 · 217694
DOI: 10.1016/j.canlet.2025.217694 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-07. Verfasst von Shanghua Cai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, 510180, Guangzhou, Guangdong, China; Guangzhou National Labor…. Hauptthemen laut MEDLINE: Metformin, Cyclic GMP, Prostatic Neoplasms, Castration-Resistant, Cyclic GMP-Dependent Protein Kinases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The castration-resistant prostate cancer (CRPC) remains an incurable disease. Metformin has demonstrated a potential therapeutic effect on CRPC. However, the poor clinical performance of metformin against cancer may be due to its clinical dose being much lower than the anticancer concentration used in pre-clinical experiments. The challenge is to determine a way to enhance sensitivity to metformin at an appropriate concentration on CRPC. In this study, a mouse model of low-dose metformin treatment for CRPC cells were established. Metabolomic-seq and transcriptomic-seq was used to investigate changes in CRPC xenografts. We discovered that low-dose metformin inhibits the progression of CRPC by regulating PDE6D, which induces alterations in purine metabolism and activates the cGMP/PKG pathway. Furthermore, we found that cells with high expression of PDE6D were more resistant to metformin. When combined with the PDE6D inhibitor TMX-4100, the inhibitory effect on tumors was enhanced, and TMX-4100 demonstrated favorable biosafety in animal models. In conclusion, we found that low-dose metformin inhibits the progression of CRPC by regulating PDE6D-induced alterations in purine metabolism and activating the cGMP/PKG pathway. Moreover, patients with high PDE6D expression may exhibit greater resistance to metformin. Combining metformin with TMX-4100 could further improve the inhibitory effects on tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, 510180, Guangzhou, Guangdong, China; Guangzhou National Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island,…
- Department of Urology, The First Dongguan Affiliated Hospital, Guangdong Medical University, 523710, Dongguan, Guangdong, China.
- Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, 510180, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Med…
- Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, 510180, Guangzhou, Guangdong, China; Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First Peopl…
- Department of Urology, Guangzhou First People's Hospital, Guangzhou Medical University, 510180, Guangzhou, Guangdong, China.
- Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, 510180, Guangzhou, Guangdong, China.
Zitieren
APA
Cai, S., Deng, Y., Zou, Z., Tian, W., Tang, Z., Li, J., Tan, Z., Wu, Z., Han, Z., Wen, B., Feng, Y., Liu, R., Zhu, X., Wu, Y., Xiao, H., He, H., Ye, J., & Zhong, W. (2025). Metformin inhibits the progression of castration-resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation. Cancer Letters, 622, 217694. https://doi.org/10.1016/j.canlet.2025.217694
Vancouver
Cai S, Deng Y, Zou Z, Tian W, Tang Z, Li J, et al. Metformin inhibits the progression of castration-resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation. Cancer Letters. 2025;622:217694. doi:10.1016/j.canlet.2025.217694
BibTeX
@article{Cai2025,
author = {Cai, Shanghua and Deng, Yulin and Zou, Zhihao and Tian, Weicheng and Tang, Zhenfeng and Li, Jinchuang and Tan, Zeheng and Wu, Zhenjie and Han, Zhaodong and Wen, Biyan and Feng, Yuanfa and Liu, Ren and Zhu, Xuejin and Wu, Yongding and Xiao, Haiyin and He, Huichan and Ye, Jianheng and Zhong, Weide},
title = {Metformin inhibits the progression of castration-resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation},
journal = {Cancer Letters},
year = {2025},
volume = {622},
pages = {217694},
doi = {10.1016/j.canlet.2025.217694}
}
EUVIMED